Article info

Download PDFPDF

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort

Authors

  • Anat Fisher Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Ken Bassett Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, British Columbia, CanadaDepartment of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada PubMed articlesGoogle scholar articles
  • James M Wright Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, British Columbia, CanadaDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada PubMed articlesGoogle scholar articles
  • M Alan Brookhart Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Hugh J Freeman Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Colin R Dormuth Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Anat Fisher; anat.fisher{at}ti.ubc.ca
View Full Text

Citation

Fisher A, Bassett K, Wright JM, et al
Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort

Publication history

  • Received April 23, 2014
  • Revised September 10, 2014
  • Accepted September 11, 2014
  • First published September 30, 2014.
Online issue publication 
September 30, 2014

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.